Drugs / MC2-25
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06132919 | Oct 2023 → Nov 2024 | vulvar lichen sclerosus | MC2 Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT05482698 | Jul 2022 → Feb 2024 | chronic kidney disease | MC2 Therapeutics | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-12-07 | MC2 Therapeutics | MC2 Therapeutics Announces Completion of Enrollment in MC2-25 Ph2 Chronic Kidney Disease-associated Pruritus Trial mc2therapeutics.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MC2-25 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05482698 ↗ |
| Route | Topical | “Topical application” NCT05482698 ↗ |